Bangalore,Ahmedabad,India : Zydus Lifesciences Ltd. announced its unaudited consolidated financial results for the quarter and nine months ended December 31st, 2025.

Key Financial Highlights

Q3 FY26 Highlights

  • Revenue from operations at Rs. 68,645 mn, up 30% over last year.
  • Research & Development (R&D) investments for the quarter stood at Rs. 6,074 mn (8.8% of revenues).
  • EBITDA for the quarter was Rs. 18,164 mn, up 31% YoY. EBITDA margin for the quarter stood at 26.5%, which is an improvement of 20 bps on a YoY basis.
  • Net Profit (Adjusted)1 for the quarter was Rs. 11,109 mn, up 9% YoY.
  • Capex (organic) for the quarter was Rs. 4,637 mn.

9M FY26 Highlights

  • Revenue from operations at Rs. 1,95,614 mn, up 17% over last year.
  • R&D investments stood at Rs. 15,750 mn (8.1% of revenues).
  • EBITDA was Rs. 59,207 mn, up 20% YoY. EBITDA margin stood at 30.3%, which is an improvement of 80 bps over the previous year.
  • Net Profit (Adjusted)1 was Rs. 38,640 mn, up 15% YoY.
  • Capex (organic) for the nine months was Rs. 13,568 mn.
  • Net Debt to Equity ratio as on 31st December 2025 was 0.11x while Net Debt to EBITDA stood at 0.36x at the end of December 2025.

Our robust performance in 3QFY26 across key businesses reinforces the strength and scalability of our base business. Our disciplined M&A and business development strategy is translating into tangible results, laying a strong foundation for sustained value creation. Anchored in patient centricity, supported by unwavering compliance and an agile supply chain, we continue to deliver quality products globally. We remain focused on consistent execution and driving long-term shareholder value.Dr. Sharvil Patel, Managing Director – Zydus Lifesciences Limited